Chemoradiation, surgery, then durvalumab for stage 3 lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 3 non-small cell lung cancer that has not spread to the lymph nodes on the other side of your chest (N3).
- You are healthy enough for daily activities (ECOG score 0 or 1).
- You have not had prior treatment with immunotherapy drugs like durvalumab, pembrolizumab, or similar.
- You do not have active autoimmune or inflammatory conditions (like lupus, Crohn's disease, or rheumatoid arthritis) that are not well controlled.
- You are willing to use effective birth control during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial gives a combination of chemotherapy and durvalumab (an immunotherapy drug) before surgery or radiation, then durvalumab alone afterward. It aims to shrink the tumor and improve outcomes for people with stage III non-small cell lung cancer that is borderline resectable.
This study looks at how the body’s immune system responds in people with stage III lung cancer (not removable by surgery) who first get chemotherapy and radiation and then receive the immunotherapy drug durvalumab for one year. It aims to learn more about the immune response and why the treatment works better for some people.
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
This trial studies whether adding durvalumab (an immune therapy) to standard chemoradiation before surgery can improve outcomes for people with stage III, resectable lung cancer. It aims to help shrink the tumor and improve chances of successful treatment.
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.